Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Virax Biolabs Group Ltd’s current trading price is -74.67% away from its 52-week high, while its distance from the 52-week low is 280.00%. The stock’s price range during this period has varied between $0.60 and $9.00. The company, active in the Healthcare sector, saw a trading volume of around 0.77 million for the day, considerably lower average daily volume of 6.0 million observed over the last three months.
Virax Biolabs Group Ltd’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $9.00 on 08/19/24, and the lowest price during the same period was recorded at $0.60 on 05/03/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Virax Biolabs Group Ltd (VRAX) has experienced a quarterly rise of 79.53% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 9.90M and boasts a workforce of 17 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.09, with a change in price of +1.23. Similarly, Virax Biolabs Group Ltd recorded 4,801,960 in trading volume during the last 100 days, posting a change of +117.14%.
How VRAX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for VRAX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.03.
VRAX Stock Stochastic Average
As of today, the raw stochastic average of Virax Biolabs Group Ltd over the past 50 days is 11.58%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 37.96%. Additionally, the Stochastic %K and %D values for the company were 46.14% and 41.28%, respectively, over the past 20 days.
VRAX Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a gain of 56.16%.However, over the last six months, we can see a weaker performance of 230.43%. Over the last 30 days, the price of VRAX has fallen by 18.13%. And in the last five days, it has surged by 49.02%.
